AirSculpt Technologies(AIRS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.4 million, down approximately 15% year-over-year, with same-store revenue declining 16% [14] - For the full year 2025, total revenue was $151.8 million, a decrease of approximately 15.8% compared to fiscal 2024 [15] - Adjusted EBITDA for Q4 was $2.5 million, representing a margin of 7.4%, an increase of $0.6 million and 2.8% margin expansion year-over-year [15] - Full year adjusted EBITDA was approximately $15 million, resulting in an adjusted EBITDA margin of approximately 10% [15] Business Line Data and Key Metrics Changes - The company reported improvements in lead and consult volumes, contributing to better revenue trends moving into 2026 [5] - Over 100 skin removal surgeries were completed in Q4 2025, with expectations for ramp-up in 2026 as capabilities expand across all locations [8] Market Data and Key Metrics Changes - The skin tightening and skin removal market is projected to be as large as fat removal, representing a long-term sales opportunity exceeding $100 million [7] - The percentage of patients using financing for procedures was approximately 50% [14] Company Strategy and Development Direction - The company is focusing on introducing new services to capture the GLP-1 market opportunity, enhancing sales and marketing strategies, and maintaining strong financial discipline [6] - Strategic exit from the only clinic outside North America was made to streamline operations [5] - The company aims to build on momentum and drive disciplined growth to create shareholder value [10] Management's Comments on Operating Environment and Future Outlook - Management noted that 2025 was a year of rebuilding and transformation, with same-store sales improving from down 22% at the start of 2025 to positive in February 2026 [5] - The company expects revenue in 2026 to range from $151 million to $157 million, reflecting approximately 3% comparable growth [17] - Management acknowledged the need to monitor the helium plasma supply situation due to geopolitical issues affecting skin tightening procedures [18] Other Important Information - The company paid down $19 million of debt in 2025, with gross debt outstanding at $56 million at year-end [16] - Cash flow from operations for the year was $3.1 million, down from $11.4 million in fiscal 2024 [17] Q&A Session Summary Question: Guidance for 1Q indicates a slight decline year-over-year, while full year 2026 revenue is expected to be up slightly. What is causing this change in seasonality? - Management indicated that trends have improved significantly, and they are focused on execution to ensure they meet their numbers [22] Question: Can the company isolate market trends for the core business outside of GLP-1 related procedures? - Management noted that the core business around body contouring and fat removal is holding steady, with GLP-1 being the next wave of change [23] Question: What feedback has the company received regarding excisional procedures from the pilot phase? - Management reported excellent results from patients and comfort from surgeons, with plans to ramp up procedures as the year progresses [27] Question: How should capital allocation be viewed going forward regarding debt pay down versus business investment? - Management emphasized the priority of maintaining a healthy balance sheet while also investing back into the business for growth initiatives [29]